- Investing Ideas
- /
- Hong Kong Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Hong Kong Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
16
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
16 companies
Innovent Biologics
Market Cap: HK$159.0b
A biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally.
1801
HK$92.90
7D
-1.1%
1Y
132.5%
Sino Biopharmaceutical
Market Cap: HK$130.9b
An investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China.
1177
HK$7.25
7D
0%
1Y
154.4%
WuXi Biologics (Cayman)
Market Cap: HK$127.6b
An investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia.
2269
HK$31.22
7D
-2.4%
1Y
181.3%
CSPC Pharmaceutical Group
Market Cap: HK$113.1b
An investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally.
1093
HK$9.66
7D
6.2%
1Y
68.9%
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$92.6b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$404.20
7D
5.8%
1Y
163.5%
Genscript Biotech
Market Cap: HK$36.2b
An investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally.
1548
HK$17.16
7D
-4.9%
1Y
44.2%
RemeGen
Market Cap: HK$36.0b
A biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States.
9995
HK$59.15
7D
-14.2%
1Y
317.7%
InnoCare Pharma
Market Cap: HK$34.9b
A biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China.
9969
HK$17.85
7D
-1.9%
1Y
289.7%
China Medical System Holdings
Market Cap: HK$31.4b
An investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China.
867
HK$12.99
7D
-3.1%
1Y
102.7%
Simcere Pharmaceutical Group
Market Cap: HK$30.9b
An investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China.
2096
HK$12.46
7D
-4.2%
1Y
134.7%
Everest Medicines
Market Cap: HK$20.2b
A biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets.
1952
HK$67.30
7D
-5.2%
1Y
257.2%
Shanghai Haohai Biological Technology
Market Cap: HK$12.2b
Shanghai Haohai Biological Technology Co., Ltd.
6826
HK$28.14
7D
-4.8%
1Y
-2.0%
Abbisko Cayman
Market Cap: HK$6.8b
Engages in the research and development of pharmaceutical products in the People’s Republic of China and the European Union.
2256
HK$10.45
7D
-0.3%
1Y
281.4%
Tong Ren Tang Technologies
Market Cap: HK$6.7b
Produces and distributes Chinese medicine products in Mainland China and Hong Kong.
1666
HK$5.15
7D
-4.3%
1Y
4.9%
Jacobson Pharma
Market Cap: HK$3.3b
Through its subsidiaries, engages in the research, development, production, sale, and distribution of medicine and drugs in Hong Kong, Mainland China, Macau, Singapore, and internationally.
2633
HK$1.67
7D
1.8%
1Y
187.9%
Jilin Province Huinan Changlong Bio-pharmacy
Market Cap: HK$1.2b
Manufactures and distributes Chinese medicines and pharmaceutical products in the People’s Republic of China.
8049
HK$2.11
7D
-7.5%
1Y
62.3%